Vaso Stock Up Following Strong Q3 Earnings and Profit Turnaround

Vaso Corp reported a sharp turnaround in Q3 2025 with revenue up 9.1% year‑over‑year to $22.7 million and net income of $1.7 million versus a $1.2 million loss a year earlier; adjusted EBITDA turned positive at $1.6 million and gross profit rose 18.2%, prompting a roughly 27% share rally post‑earnings. Growth was broad‑based—professional sales services rose 18.7% (helped by higher equipment deliveries from GE HealthCare), IT was up modestly on network services, and equipment revenue increased 8% driven by higher ARCS software subscription revenue in the U.S.—while China equipment deliveries softened. Cash generation strengthened (operating cash flow $2.8 million in the quarter and $9.0 million YTD; cash $34.9 million) and rising deferred revenue and subscription income underpin management’s expectation of topline stability, though the company provided no formal guidance and exposure to China equipment demand remains a key risk.

Analysis

Shares of Vaso Corporation rallied 27.3% following Q3 2025 results that showed a clear turnaround: revenue rose 9.1% year‑over‑year to $22.7 million and net income swung to $1.7 million from a $1.2 million loss a year earlier, outpacing the S&P 500’s 2.2% decline over the same post‑earnings window. Adjusted EBITDA returned to positive $1.6 million versus a prior‑year loss of $1.2 million, driven by higher gross profit of $13.9 million (up 18.2%) and operating income improving to $1.5 million from a $1.4 million loss.

Operating cash flow strengthened to $2.8 million in the quarter and $9.0 million year‑to‑date (vs. $3.6 million YTD 2024), and cash on hand stood at $34.9 million, supporting liquidity while SG&A rose 7% to $12.2 million mainly from personnel costs. Management emphasized rising deferred revenue and subscription (ARCS) income as supporting topline stability, but the company declined to provide formal forward guidance.

Revenue growth was broad‑based: professional sales services +18.7% (benefitting from GE HealthCare deliveries), IT +1.2% (network services resilience), and equipment +8% led by U.S. ARCS subscriptions while China equipment deliveries weakened. Key risks are the lack of formal guidance and exposure to China demand; investors should watch deferred revenue trends, subscription renewal dynamics and GE HealthCare order cadence for evidence the margin recovery is sustainable.

Key Decisions for Investors

• Consider a measured accumulation given the return to profitability, stronger cash flow and $34.9M cash balance, but scale in rather than chase after the ~27% post‑earnings rally
• Monitor deferred revenue growth, subscription (ARCS) mix and commentary at the Dec. 17 shareholders meeting as primary indicators of sustainability and be prepared to trim or hedge if deferred revenue stalls or China equipment deliveries deteriorate
• Use downside protection or set hedges (options/stop‑loss) because management provided no formal guidance and SG&A pressure and China exposure create execution risk